• Users Online: 97
  • Print this page
  • Email this page
Export selected to
Endnote
Reference Manager
Procite
Medlars Format
RefWorks Format
BibTex Format
   Table of Contents - Current issue
Coverpage
January-March 2023
Volume 6 | Issue 1
Page Nos. 1-15

Online since Thursday, March 30, 2023

Accessed 6,412 times.

PDF access policy
Journal allows immediate open access to content in HTML + PDF
View as eBookView issue as eBook
Access StatisticsIssue statistics
RSS FeedRSS
Hide all abstracts  Show selected abstracts  Export selected to  Add to my list
EDITORIAL  

Survival trends for patients with primary brain tumors worldwide: What have we learnt? p. 1
Michael Weller, Emilie Le Rhun
DOI:10.4103/glioma.glioma_1_23  
[HTML Full text]  [PDF]  [Mobile Full text]  [EPub]  [Sword Plugin for Repository]Beta
REVIEWS Top

Current status of clinical application of immunotherapy in the treatment of glioma: A narrative review p. 3
Qiuzi Chen, Peng Ren, Guohao Huang, Zuoxin Zhang, Jean-Philippe Hugnot, Shengqing Lv
DOI:10.4103/glioma.glioma_2_23  
Glioma is a common type of brain tumor. Current treatment for glioma includes surgical resection, radiotherapy, chemotherapy, and tumor-treating fields. The application of immunotherapy to treat glioma is still far from satisfactory in the clinic. Here, we review the mechanisms of immunotherapy for glioma (including immune checkpoint inhibitor, chimeric antigen receptor-T-cell, tumor vaccine, and oncolytic virus) and the results of completed clinical trials, and will discuss the current status of immunotherapy and possible future directions.
[ABSTRACT]  [HTML Full text]  [PDF]  [Mobile Full text]  [EPub]  [Sword Plugin for Repository]Beta

Research progress in the treatment of glioblastoma by an oncolytic virus: A narrative review p. 9
Xiangxiang Shao, Wei Ni, Xiaobin Xu, Yuanyuan Luo
DOI:10.4103/glioma.glioma_3_23  
Glioblastoma is the most common malignant tumor in the adult primary central nervous system. It has a strong proliferative ability, high recurrence rate, and high malignant degree. Despite standard radiotherapy combined with temozolomide chemotherapy, the prognosis was poor, with a 5-year survival of <10%. Therefore, more effective treatments need to be explored. Oncolytic viruses (OVs) have attracted the attention of researchers because of their unique targeting, safety, and antitumor effects. OV therapy has achieved remarkable efficacy in the treatment of many kinds of malignant tumors, and it has also made great progress in the treatment of glioblastoma. This article reviews the recent clinical research progress of OVs in the treatment of glioblastoma.
[ABSTRACT]  [HTML Full text]  [PDF]  [Mobile Full text]  [EPub]  [Sword Plugin for Repository]Beta
CORRIGENDUM Top

Corrigendum: The protocol for the consensuses of Chinese experts on glioma multidisciplinary team management p. 15

DOI:10.4103/glioma.glioma_4_23  
[HTML Full text]  [PDF]  [Mobile Full text]  [EPub]  [Sword Plugin for Repository]Beta